Session » Systemic Sclerosis and Related Disorders – Clinical Poster I

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 797

Absolute Reduction of Peripheral CD4+ Regulatory T Cells in Patients with Systemic Sclerosis and Its Restoration By Short-Term and Low Dose IL-2 Treatment

9:00AM-11:00AM: Abstract Number: 800

Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD

9:00AM-11:00AM: Abstract Number: 801

Cardiac Autonomic Modulation at Rest and during Orthostatic Stress in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 788

Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 793

Clinical Associations of Anti-U11/U12 (RNPC-3) Autoantibodies in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 786

Comparison of Nailfold Microvascular Damage in Mixed Connective Tissue Disease Versus Systemic Sclerosis Patients during a Three Year Follow-up

9:00AM-11:00AM: Abstract Number: 796

Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis

9:00AM-11:00AM: Abstract Number: 805

Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival

9:00AM-11:00AM: Abstract Number: 806

Estradiol Levels Are Elevated in Older Men with Diffuse Cutaneous SSc and Are Associated with Decreased Survival

9:00AM-11:00AM: Abstract Number: 792

Evaluation of Esophageal Dysmotility in Systemic Sclerosis: Clinical VALUE of Computed Tomography

9:00AM-11:00AM: Abstract Number: 795

Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort

9:00AM-11:00AM: Abstract Number: 790

Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet

9:00AM-11:00AM: Abstract Number: 794

Identification of an Immunodominant Epitope on Rnpc-3 As a Target of Autoantibodies in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 811

Identification of Risk Factors for Gastric Antral Vascular Ectasia (GAVE) Among Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 812

Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide

9:00AM-11:00AM: Abstract Number: 787

Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?

9:00AM-11:00AM: Abstract Number: 808

Mean Number of Nailfold Capillaries Is Associated with Disease Activity at 6 Months Follow-up in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 814

NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 798

Predominant Fasciitis and Mild Intramuscular Edema on Muscle Magnetic Resonance Imaging in Scleroderma-Associated Myopathy

9:00AM-11:00AM: Abstract Number: 804

Prevalence of Echocardiographic Abnormalities in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 813

Prevalence of Gastroesophageal Disease in Systemic Sclerosis and Its Impact on Lung Disease: Fact or Fiction

9:00AM-11:00AM: Abstract Number: 802

Prognostic Significance of Bicaudal D2 Antibodies in Sistemic Sclerosis (SSc) Patients

9:00AM-11:00AM: Abstract Number: 799

Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the Eustar Database

9:00AM-11:00AM: Abstract Number: 791

Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients

9:00AM-11:00AM: Abstract Number: 810

Sexual Dysfunction in Women with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 807

The Effects of DNA Methylation on Differential Expression in Dermal Fibroblasts from African-American Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 809

The Lymphangiogenetic Factors VEGF-C, CCL21 and Ang-2 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 789

The Relationship between YKL-40 and Vascular Endothelial Growth Factor in Angiogenesis in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 803

Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].